Ignite Creation Date:
2024-05-06 @ 7:52 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06162533
Status:
COMPLETED
Last Update Posted:
2023-12-08
First Post:
2023-11-30
Brief Title:
Severe Acute Respiratory Syndrome Coronavirus 2 Re-Infection Risk and Vaccine Efficacy in Austria
Sponsor:
Medical University of Graz
Organization:
Medical University of Graz
Study Overview
Official Title:
SARS-CoV-2 Re-Infection Risk and Vaccine Efficacy in Austria SARIVA Study
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SARIVA
Brief Summary:
The coronavirus disease 2019 COVID-19 pandemic was caused by the severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 virus In this study we aim to evaluate how strong and how long are individuals in Austria after vaccination andor infection with SARS-CoV-2 protected against COVID-19 disease
In this project we will analyze national health data from all inhabitants of Austria about 9 million persons during the COVID-19 pandemic The population of Austria will be stratified into different groups according to previous vaccinations against SARS-CoV-2 and previous SARS-CoV-2 infections
We primarily evaluate how strong and how long after vaccination against SARS-CoV-2 andor infection with SARS-CoV-2 the risk for COVID-19 deaths is reduced or altered as compared to less vaccinated andor infected persons As secondary study aims we perform such analyses also for SARS-CoV-2 infections hospitalizations and intensive care unit ICU stays with or due to SARS-CoV-2 These analyses will be performed during different time periods of the COVID-19 pandemic and we will also perform various subgroup analyses as for example according to age and gender Given that antibodies against SARS-CoV-2 are usually detected after vaccination andor infection we will use such antibody data from blood donors in Tyrol to elucidate how well the national health data on SARS-CoV-2 infections and vaccinations match with the respective antibody data and how well these antibody data indicate risk of COVID-19 deaths and infections
We will calculate the probability of dying due to a SARS-CoV-2 infection caseinfection fatality rate for different times of the COVID-19 pandemic in order to document the health threat due to SARS-CoV-2 Based on all these data we will calculate how many persons have to be vaccinated against SARS-CoV-2 to prevent one COVID-19 death at different times during this COVID-19 pandemic We will consider the respective COVID-19 policies such as mask mandates lock-downs SARS-CoV-2 test mandates in our analyses and will evaluate the impact of these policies on COVID-19 deaths and diseases In addition we will evaluate data on total mortality according to the number of SARS-CoV-2 vaccinations andor infections and we will aim to collaborate with other research groups in order to extend our analyses
In conclusion the results of this study should provide an overview on the COVID-19 pandemic with respect to protection conferred by vaccinations and previous SARS-CoV-2 infections as well as the health threat of SARS-CoV-2 in order to provide knowledge for future COVID-19 policy and future pandemics
In this project we will analyze national health data from all inhabitants of Austria about 9 million persons during the COVID-19 pandemic The population of Austria will be stratified into different groups according to previous vaccinations against SARS-CoV-2 and previous SARS-CoV-2 infections
We primarily evaluate how strong and how long after vaccination against SARS-CoV-2 andor infection with SARS-CoV-2 the risk for COVID-19 deaths is reduced or altered as compared to less vaccinated andor infected persons As secondary study aims we perform such analyses also for SARS-CoV-2 infections hospitalizations and intensive care unit ICU stays with or due to SARS-CoV-2 These analyses will be performed during different time periods of the COVID-19 pandemic and we will also perform various subgroup analyses as for example according to age and gender Given that antibodies against SARS-CoV-2 are usually detected after vaccination andor infection we will use such antibody data from blood donors in Tyrol to elucidate how well the national health data on SARS-CoV-2 infections and vaccinations match with the respective antibody data and how well these antibody data indicate risk of COVID-19 deaths and infections
We will calculate the probability of dying due to a SARS-CoV-2 infection caseinfection fatality rate for different times of the COVID-19 pandemic in order to document the health threat due to SARS-CoV-2 Based on all these data we will calculate how many persons have to be vaccinated against SARS-CoV-2 to prevent one COVID-19 death at different times during this COVID-19 pandemic We will consider the respective COVID-19 policies such as mask mandates lock-downs SARS-CoV-2 test mandates in our analyses and will evaluate the impact of these policies on COVID-19 deaths and diseases In addition we will evaluate data on total mortality according to the number of SARS-CoV-2 vaccinations andor infections and we will aim to collaborate with other research groups in order to extend our analyses
In conclusion the results of this study should provide an overview on the COVID-19 pandemic with respect to protection conferred by vaccinations and previous SARS-CoV-2 infections as well as the health threat of SARS-CoV-2 in order to provide knowledge for future COVID-19 policy and future pandemics
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None